GlassScriptPhysician profile
Heloise Labuschagne
NPI 1821470832
$5,173.25
in general payments reported to CMS, 2019-2025
31 companies · $1,773 in 2025
The $1,773 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $99.99 · 2021: $230 · 2022: $824 · 2023: $1,359 · 2024: $887 · 2025: $1,773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,892 · Education: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,891.79 |
| Education | $128.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,680.60 | 2021-2025 | Fasenra, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $479.74 | 2021-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $471.64 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $460.16 | 2021-2025 | Ofev, Spiriva Respimat, Jascayd |
| Actelion Pharmaceuticals US, INC. | $279.71 | 2021-2025 | Opsumit, Uptravi |
| Grifols USA, LLC | $267.20 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Genentech USA, INC. | $199.57 | 2019-2025 | Xolair |
| Genzyme Corporation | $187.35 | 2023-2025 | |
| Mylan Specialty L.P. | $180.78 | 2023-2024 | Yupelri |
| Resmed Corp | $111.58 | 2023-2025 | |
| Baxter Healthcare | $104.34 | 2023-2025 | Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care, Hillrom - Vest System Model 205 Acute Care |
| Viatris Specialty LLC | $91.21 | 2025 | Yupelri |
| Mallinckrodt Hospital Products INC. | $69.32 | 2021-2025 | Acthar |
| Lilly USA, LLC | $64.42 | 2025 | Zepbound |
| Insmed, INC. | $61.59 | 2025 | Arikayce |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $56.17 | 2025 | Glassia |
| Abbvie INC. | $40.38 | 2022 | |
| Novartis Pharmaceuticals Corporation | $38.31 | 2023-2024 | |
| Inspire Medical Systems, INC. | $38.21 | 2025 | Inspire |
| Pfizer INC. | $37.57 | 2023-2024 | |
| Amgen INC. | $37.24 | 2025 | Tezspire |
| Advanced Respiratory, INC | $32.64 | 2021 | |
| Tactile Systems Technology INC | $31.49 | 2025 | Nimbl, Flexitouch Plus |
| Verona Pharma, INC. | $27.90 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $19.96 | 2025 | Tyvaso |
| Electromed, INC. | $19.80 | 2025 | Smartvest |
| Gilead Sciences, INC. | $19.28 | 2024 | Veklury |
| Zoll Respicardia, INC. | $18.59 | 2023 | Remede System |
| Teva Pharmaceuticals USA, INC. | $17.60 | 2022 | |
| Pulmonx Corporation | $15.52 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Janssen Pharmaceuticals, INC | $13.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heloise Labuschagne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.